Symbiotec Pharmalab (NSE: SYMBIOTEC, BSE: 544889) is an Indore, Madhya Pradesh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹7,871 Cr, it ranks #652 by market cap among the 6,197 Indian listed companies on FinBizNet, and #20 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,546.20 (as of 9 Nov 2026), the share price is 3.9% below its 52-week high of ₹1,609.00 and 65.5% above its 52-week low of ₹934.20.
| Current Price | ₹1,546.20 |
|---|---|
| Market Cap | ₹7,871 Cr |
| NSE Symbol | SYMBIOTEC |
| BSE Code | 544889 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 64.5 |
| Return on Assets | 6.96% |
| 52-Week Range | ₹934.20 – ₹1,609.00 |
| Beta (1Y) | -3.22 |
| Headquarters | Indore, Madhya Pradesh |
| Website | www.symbiotec.com |
| Revenue | ₹280 Cr |
|---|---|
| Net Profit | ₹52 Cr |
| Net Margin | 18.5% |
| EPS (Basic) | ₹8.20 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Promoters held 33.28% of Symbiotec Pharmalab's shares as of Sept 2026, unchanged from Aug 2026. Delivery averaged 35.5% of traded volume across 16 NSE sessions (15 Oct 2026 – 9 Nov 2026).
Symbiotec Pharma Lab Pvt. Ltd. develops, manufactures, and markets active pharmaceutical ingredients (APIs), with a primary focus on cortico-steroids and steroid-hormone APIs in both sterile and non-sterile forms. The company synthesizes progestin, estrone, testosterone, their derivatives, and anabolic steroids, supplying these in commercial volumes globally. It offers APIs and intermediate pharmaceutical products for therapeutic areas such as gastrointestinal ailments, cardiovascular disease, pain management, paediatrics, anti-infective, and dermatology. The company provides contract manufacturing (CMO) and contract development and manufacturing (CDMO) services, particularly for fermentation-based APIs, and operates large-scale manufacturing facilities with dedicated research and development and quality control laboratories. Its product portfolio includes APIs outside the cortico-steroids and hormone categories, with several products under development. The company serves clients in th
1. Manufacturing of Active Pharmaceuticals Ingredients (API) and Intermediates-This segment engages in the manufacturing of active pharmaceuticals ingredients and intermediates. 2. NA-NA 3. NA-NA 4. NA-NA
1. Manufacturing of Active Pharmaceuticals Ingredients (API) and Intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,24,682 Cr | 37 | 14.72% | ₹16,199 Cr | +11.6% |
| Laurus Labs Ltd | ₹1,26,865 Cr | 142.7 | 17.74% | ₹2,206 Cr | +151.6% |
| Zydus Lifesciences Ltd | ₹1,23,740 Cr | 24.8 | 18.32% | ₹7,910 Cr | +23.9% |
| Cipla Limited | ₹1,12,054 Cr | 28.9 | 11.74% | ₹7,404 Cr | -7.1% |
| Dr.Reddys Lab | ₹1,11,653 Cr | 26.1 | 11.52% | ₹8,698 Cr | +15.8% |
| Mankind Pharma | ₹1,02,485 Cr | 53.6 | 12.45% | ₹4,338 Cr | +11.2% |
| Aurobindo Pharma Ltd. | ₹96,882 Cr | 27.9 | 9.93% | ₹10,263 Cr | +62.9% |
| Lupin Ltd | ₹91,289 Cr | 17.1 | 26.91% | ₹7,827 Cr | +2.1% |
| Symbiotec Pharmalab | ₹7,871 Cr | 64.5 | — | ₹280 Cr | — |
Listed by market capitalisation. Ratios are shown for context only.
Symbiotec Pharmalab is trading at ₹1,546.20, with a market capitalisation of ₹7,871 Cr.
Symbiotec Pharmalab operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Symbiotec Pharmalab has a P/E of 64.5.
Symbiotec Pharmalab is listed on the NSE under the symbol SYMBIOTEC and on the BSE under the scrip code 544889.
In Q2 FY27, Symbiotec Pharmalab reported revenue of ₹280 Cr and net profit of ₹52 Cr, with basic EPS of ₹8.2 (consolidated, parsed from the company's exchange filing).
Promoters held 33.28% of Symbiotec Pharmalab's shares as of Sept 2026, unchanged from Aug 2026.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.